Welcome to our dedicated page for Abvc Biopharma news (Ticker: ABVC), a resource for investors and traders seeking the latest updates and insights on Abvc Biopharma stock.
ABVC BioPharma, Inc. develops clinical-stage therapeutic products in ophthalmology, central nervous system disorders, and oncology/hematology. Its pipeline includes botanically derived drug candidates and the ophthalmology medical device Vitargus, with disclosed programs tied to Major Depressive Disorder, Attention Deficit Hyperactivity Disorder, Non-Small Cell Lung Cancer, and retinal surgery applications.
Recurring company news covers global licensing agreements, milestone and licensing-fee receipts, partner activity involving BioLite, BioFirst, Rgene, AiBtl BioPharma, ForSeeCon Eye Corporation, and OncoX BioPharma, and updates on clinical development, regulatory preparation, and reported financial results.
WallachBeth Capital has completed an underwritten public offering of 1,100,000 units for ABVC BioPharma at $6.25 per unit, raising $6.875 million in gross proceeds. Each unit consists of one share of common stock, a Series A warrant with an exercise price of $6.30, and a Series B warrant at $10.00. Additionally, ABVC granted underwriters a 45-day option for an extra 165,000 shares at $6.23 and warrants at $0.01. The common shares began trading on NASDAQ on August 3, 2021. WallachBeth acted as the sole book-running manager for this offering.
ABVC BioPharma, a clinical-stage biopharmaceutical company, announced its firm commitment offering of 1,100,000 Units at $6.25 per unit, totaling $6.875 million. Each Unit includes one common share and two types of warrants (Series A and B) with varying exercise prices and conditions. The company has granted underwriters a 45-day option for an additional 165,000 shares. Net proceeds will primarily fund clinical trials and general business expenses, potentially for strategic transactions. The shares began trading on NASDAQ on August 3, 2021, under the ticker symbol 'ABVC.'